 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1994 | Volume 120 Issue 1 | Pages 18-25
Objective: To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node-positive breast cancer and to determine how obesity relates to other commonly used prognostic indicators.
Design: Retrospective review of the clinical characteristics and clinical course of 735 patients with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy protocols. Univariate and multivariate analyses were used to determine the prognostic implications of obesity defined by weight and height tables and body mass index. In addition, we analyzed the relation between obesity and other known prognostic indicators for patients with primary breast cancer.
Setting: A comprehensive cancer center.
Patients: 735 patients with lymph node-positive primary breast cancer who were treated using three consecutive fluorouracil-doxorubicin-cyclophosphamide-containing adjuvant chemotherapy protocols and for whom complete data on weight, height, standard prognostic factors, and outcome were available.
Main Outcome Measurements: Disease-free and overall survival for the entire group and obese and nonobese subgroups.
Results: 24 percent of patients were more than 20% overweight. With a median follow-up of 10.7 years, the estimated 10-year, disease-free rate for patients not more than 20% overweight was 54% (95% CI, 50% to 58%) compared with 40% (CI, 33% to 47%) for remaining patients classified as obese. Although obese patients tended to have somewhat less favorable prognoses based on standard prognostic criteria, a proportional-hazards regression model adjusting for other factors indicated that risk for disease recurrence among obese patients was 1.33 times that of the nonobese population (CI, 1.05 to 1.68).
Conclusions: Obesity is an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. The effect of dietary interventions to reduce body weight on the outcome of breast cancer therapy must be investigated.
Author and Article Information
From The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
ARTICLE
Obesity as an Adverse Prognostic Factor for Patients Receiving Adjuvant Chemotherapy for Breast Cancer
Requests for Reprints: G.N. Hortobagyi, MD, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 56, Houston, TX, 77030.
Acknowledgments: The authors thank Lidia Vogelsang for secretarial assistance and Kimberly Herrick for editorial assistance.
Grant Support: In part by grant CA-16672 from the National Cancer Institute.
This article has been cited by other articles:
|
|
 |
|
  J. K. Litton, A. M. Gonzalez-Angulo, C. L. Warneke, A. U. Buzdar, S.-W. Kau, M. Bondy, S. Mahabir, G. N. Hortobagyi, and A. M. Brewster Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer J. Clin. Oncol., September 1, 2008; 26(25): 4072 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Pierce, M. L. Stefanick, S. W. Flatt, L. Natarajan, B. Sternfeld, L. Madlensky, W. K. Al-Delaimy, C. A. Thomson, S. Kealey, R. Hajek, et al. Greater Survival After Breast Cancer in Physically Active Women With High Vegetable-Fruit Intake Regardless of Obesity J. Clin. Oncol., June 10, 2007; 25(17): 2345 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Demirkan, A. Alacacioglu, and U. Yilmaz Relation of Body Mass Index (BMI) to Disease Free (DFS) and Distant Disease Free Survivals (DDFS) Among Turkish Women with Operable Breast Carcinoma Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Andrykowski, A. O. Beacham, and P. B. Jacobsen Prospective, Longitudinal Study of Leisure-Time Exercise in Women with Early-Stage Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 430 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hijiya, J. C. Panetta, Y. Zhou, E. P. Kyzer, S. C. Howard, S. Jeha, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, M. M. Hudson, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia Blood, December 15, 2006; 108(13): 3997 - 4002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kjaerbye-Thygesen, K. Frederiksen, E. V. Hogdall, E. Glud, L. Christensen, C. K. Hogdall, J. Blaakaer, and S. K. Kjaer Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 798 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Tao, X.-O. Shu, Z. X. Ruan, Y.-T. Gao, and W. Zheng Association of Overweight with Breast Cancer Survival Am. J. Epidemiol., January 15, 2006; 163(2): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Ladas, N. Sacks, L. Meacham, D. Henry, L. Enriquez, G. Lowry, R. Hawkes, G. Dadd, and P. Rogers A Multidisciplinary Review of Nutrition Considerations in the Pediatric Oncology Population: A Perspective From Children's Oncology Group Nutr Clin Pract, August 1, 2005; 20(4): 377 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Griggs, M. E. S. Sorbero, and G. H. Lyman Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy Arch Intern Med, June 13, 2005; 165(11): 1267 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Holmes, W. Y. Chen, D. Feskanich, C. H. Kroenke, and G. A. Colditz Physical Activity and Survival After Breast Cancer Diagnosis JAMA, May 25, 2005; 293(20): 2479 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Kroenke, W. Y. Chen, B. Rosner, and M. D. Holmes Weight, Weight Gain, and Survival After Breast Cancer Diagnosis J. Clin. Oncol., March 1, 2005; 23(7): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Lange, R. B. Gerbing, J. Feusner, J. Skolnik, N. Sacks, F. O. Smith, and T. A. Alonzo Mortality in Overweight and Underweight Children With Acute Myeloid Leukemia JAMA, January 12, 2005; 293(2): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Garofalo, D. Sisci, and E. Surmacz Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells Clin. Cancer Res., October 1, 2004; 10(19): 6466 - 6475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Berclaz, S. Li, K. N. Price, A. S. Coates, M. Castiglione-Gertsch, C.-M. Rudenstam, S. B. Holmberg, J. Lindtner, D. Erien, J. Collins, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience Ann. Onc., June 1, 2004; 15(6): 875 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Eng-Wong, S. D. Hursting, D. Venzon, S. N. Perkins, and J. A. Zujewski Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1468 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Dignam, K. Wieand, K. A. Johnson, B. Fisher, L. Xu, and E. P. Mamounas Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer J Natl Cancer Inst, October 1, 2003; 95(19): 1467 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Rock and W. Demark-Wahnefried Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence J. Clin. Oncol., August 1, 2002; 20(15): 3302 - 3316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, E. Aiello, and A. McTiernan Weight Loss in Breast Cancer Patient Management J. Clin. Oncol., February 15, 2002; 20(4): 1128 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF]
|
|
Article
